EP2200574B1 - Neue verwendung von panduratin-derivaten oder kaempferia pandurata-extrakt damit - Google Patents
Neue verwendung von panduratin-derivaten oder kaempferia pandurata-extrakt damit Download PDFInfo
- Publication number
- EP2200574B1 EP2200574B1 EP08840361.3A EP08840361A EP2200574B1 EP 2200574 B1 EP2200574 B1 EP 2200574B1 EP 08840361 A EP08840361 A EP 08840361A EP 2200574 B1 EP2200574 B1 EP 2200574B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- kaempferia pandurata
- panduratin
- food
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000060701 Kaempferia pandurata Species 0.000 title claims description 134
- 235000013412 Kaempferia pandurata Nutrition 0.000 title claims description 134
- 239000000284 extract Substances 0.000 title claims description 106
- 229930193739 panduratin Natural products 0.000 title claims description 93
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 64
- 239000000126 substance Substances 0.000 claims description 44
- 230000037303 wrinkles Effects 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 30
- 230000032683 aging Effects 0.000 claims description 29
- 108010035532 Collagen Proteins 0.000 claims description 28
- 102000008186 Collagen Human genes 0.000 claims description 28
- 229920001436 collagen Polymers 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 27
- 239000002537 cosmetic Substances 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- 235000015872 dietary supplement Nutrition 0.000 claims description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- 238000003786 synthesis reaction Methods 0.000 claims description 21
- 230000011382 collagen catabolic process Effects 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000001737 promoting effect Effects 0.000 claims description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 claims description 3
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 description 87
- 206010040954 Skin wrinkling Diseases 0.000 description 49
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 28
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- LYDZCXVWCFJAKQ-ZFGGDYGUSA-N Panduratin A Chemical compound OC1=CC(OC)=CC(O)=C1C(=O)[C@H]1[C@H](C=2C=CC=CC=2)CC=C(C)[C@H]1CC=C(C)C LYDZCXVWCFJAKQ-ZFGGDYGUSA-N 0.000 description 23
- LYDZCXVWCFJAKQ-UHFFFAOYSA-N nicolaioidesin A Natural products OC1=CC(OC)=CC(O)=C1C(=O)C1C(C=2C=CC=CC=2)CC=C(C)C1CC=C(C)C LYDZCXVWCFJAKQ-UHFFFAOYSA-N 0.000 description 23
- 102100023132 Transcription factor Jun Human genes 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 19
- 238000009472 formulation Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 108010050808 Procollagen Proteins 0.000 description 14
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 14
- 239000000469 ethanolic extract Substances 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 230000037333 procollagen synthesis Effects 0.000 description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 230000003712 anti-aging effect Effects 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- 239000002304 perfume Substances 0.000 description 9
- DIHCGASLQARQMP-UHFFFAOYSA-N (+)-isopanduratin A Natural products COC1=CC(O)=CC(O)=C1C(=O)C1C(C=2C=CC=CC=2)CC=C(C)C1CC=C(C)C DIHCGASLQARQMP-UHFFFAOYSA-N 0.000 description 8
- DIHCGASLQARQMP-ZFGGDYGUSA-N (2,4-dihydroxy-6-methoxyphenyl)-[(1r,2s,6r)-3-methyl-2-(3-methylbut-2-enyl)-6-phenylcyclohex-3-en-1-yl]methanone Chemical compound COC1=CC(O)=CC(O)=C1C(=O)[C@H]1[C@H](C=2C=CC=CC=2)CC=C(C)[C@H]1CC=C(C)C DIHCGASLQARQMP-ZFGGDYGUSA-N 0.000 description 8
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 8
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 206010051246 Photodermatosis Diseases 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 239000009727 isopanduratin A Substances 0.000 description 8
- 230000008845 photoaging Effects 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- AYPOOQWQTQIRFW-UHFFFAOYSA-N (+)-Hydroxypanduratin A Natural products C1C=C(C)C(CC=C(C)C)C(C(=O)C=2C(=CC(O)=CC=2O)O)C1C1=CC=CC=C1 AYPOOQWQTQIRFW-UHFFFAOYSA-N 0.000 description 7
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 7
- 102100027584 Protein c-Fos Human genes 0.000 description 7
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- AYPOOQWQTQIRFW-ZRCGQRJVSA-N [(1r,2s,6r)-3-methyl-2-(3-methylbut-2-enyl)-6-phenylcyclohex-3-en-1-yl]-(2,4,6-trihydroxyphenyl)methanone Chemical compound C1([C@H]2[C@@H]([C@@H](C(=CC2)C)CC=C(C)C)C(=O)C=2C(=CC(O)=CC=2O)O)=CC=CC=C1 AYPOOQWQTQIRFW-ZRCGQRJVSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 102000043136 MAP kinase family Human genes 0.000 description 6
- 108091054455 MAP kinase family Proteins 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 5
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000002026 chloroform extract Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 5
- 239000002035 hexane extract Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000003746 surface roughness Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 230000037330 wrinkle prevention Effects 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 description 1
- RTIXKCRFFJGDFG-UHFFFAOYSA-N Chrysin Natural products C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004085 Kaempferia angustifolia Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- FGUBFGWYEYFGRK-HNNXBMFYSA-N Pinocembrin Natural products Cc1cc(C)c2C(=O)C[C@H](Oc2c1)c3ccccc3 FGUBFGWYEYFGRK-HNNXBMFYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098345 Triticum durum Species 0.000 description 1
- 235000007264 Triticum durum Nutrition 0.000 description 1
- 206010046461 Urethral pain Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical class C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- URFCJEUYXNAHFI-ZDUSSCGKSA-N pinocembrin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-ZDUSSCGKSA-N 0.000 description 1
- LOYXTWZXLWHMBX-VOTSOKGWSA-N pinocembrin chalcone Chemical compound OC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 LOYXTWZXLWHMBX-VOTSOKGWSA-N 0.000 description 1
- -1 pinostribin Chemical compound 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- CEAYCPAHSNTNGO-UHFFFAOYSA-M sodium;ethane-1,2-diamine;acetate Chemical compound [Na+].CC([O-])=O.NCCN CEAYCPAHSNTNGO-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Definitions
- the present invention relates to a novel use of panduratin derivatives or a Kaempferia pandurata extract comprising the same in non-therapeutic methods.
- Aging is largely classified into natural aging, or intrinsic aging, and extrinsic aging. Natural aging is caused by hereditary factors and is hard to control, whereas extrinsic aging is caused by environmental factors and can be controlled relatively easily. Accordingly, researches have continued to prevent extrinsic aging. Especially, researches on the prevention of wrinkles caused by extrinsic photoaging due to long-term exposure to UV are drawing attentions [ Gilchre st B.A., J. Am. Acad. Dermatol., 1989: 21: 610-613 ]. The photoaging, or extrinsic skin aging, is clinically characterized by rough and inelastic skin, irregular pigmentation and deep wrinkles.
- Some of active ingredients for treating wrinkles and preventing aging which have been developed to date, have problems in that they cannot be used as cosmetic materials, are very unstable and are not easy to deliver to the skin. Accordingly, a special stabilizing system and delivery system are required, and the effect thereof on treating skin wrinkles is not visible. For this reason, interest in skin-protecting agents containing retinoid has recently been increased.
- retinoid is used as a means for solving photoaging phenomena, such as wrinkles resulting from sunlight, skin thickening, skin drooping and a decrease in skin elasticity.
- retinoid has a problem in that it is a very unstable compound, which is sensitive to UV light, moisture, heat and oxygen such that a chemical change therein easily occurs. In attempts to solve this problem, studies focused on developing effective components derived from natural resources have been conducted.
- Kaempferia pandurata also known as Boesenbergia pandurata, is a plant of the Zingiberaceae family. Its rhizome is widely used to treat cold, enteritis, skin disease and urethral pain. Kaempferia pandurata contains pinocembrin chalcone, cardamonin, pinocembrin, pinostribin, 4-hydroxypanduratin A, panduratin A, and the like. These components are reported to have anti-cancer effect [ Trakoontivakorn, G., et al., J. Agri.
- Korean Patent No. 492034 discloses an antimicrobial and an oral composition for the prevention and treatment of caries and periodontitis comprising panduratin derivatives such as isopanduratin A.
- panduratin derivatives such as isopanduratin A.
- wrinkle treatment effect or anti-aging effect of panduratin derivatives or a Kaempferia pandurata extract comprising the same have never been reported yet.
- JP2007186431 discloses a method for suppressing oxidation in the body, using Boesenbergia rotunda (Kaempferia pandurata) or 4-hydroxypanduratin in a medicinal or food composition. Ageing is mentioned very briefly.
- JP2000316526 discloses a food composition for improving health, comprising extracts of Boesenbergia pandurata.
- WO 02/15860 and KR 2004 0108081 disclose the use of antioxidant compounds in preventing/treating skin ageing.
- JP2001261545 discloses a skin care preparation for the prevention of chapped skin symptoms due to diseases such as psoriasis, contact dermatitis etc., which comprises an extract of Kaempferia angustifolia.
- JP09030945 discloses a dermal preparation comprising an extract of Boesenbergia pandurata for skin whitening and also to prevent pigmentation after sunburn.
- panduratin derivatives or a Kaempferia pandurata extract comprising the same have such an activity and accomplished the present invention.
- the present invention provides non-therapeutic methods for promoting collagen synthesis and for inhibiting collagen degradation, and also non-therapeutic uses of cosmetic compositions, and non-therapeutic uses of a food and non-therapeutic uses of nutritional supplements, all for preventing and treating wrinkles, or achieving anti-aging effects comprising the use of a panduratin derivative selected from the group consisting of the compounds represented by the following Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same:
- the present invention provides a non-therapeutic use of a cosmetic composition, a non-therapeutic use of a food and a non-therapeutic use of a nutritional supplement, all of which promote collagen synthesis, for preventing or treating wrinkle, or for preventing aging, using a panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same.
- the present invention provides a non-therapeutic use of a cosmetic composition, a food or a nutritional supplement, all of which inhibit collagen degradation, using a panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same.
- the present invention provides a non-therapeutic method for promoting collagen synthesis of a panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same.
- the present invention provides a non-therapeutic method for inhibiting collagen degradation of a panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same.
- the present invention describes non-therapeutic uses of a cosmetic composition, of a food and of a nutritional supplement, and as well non-therapeutic methods for inhibiting collagen synthesis and for promoting collagen synthesis, each containing a panduratin derivative selected from the group consisting of the compounds represented by the following Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same:
- the present invention provides a non-therapeutic use of a cosmetic composition, a food or a nutritional supplement which promotes collagen synthesis for preventing or treating wrinkle, or for preventing aging, using a panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same.
- the present invention provides a non-therapeutic use of a cosmetic composition, a food or a nutritional supplement which inhibits collagen degradation for preventing or treating wrinkle, or for preventing aging, using a panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same.
- the present invention also provides a method for promoting collagen synthesis of a panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same, thereby particularly preventing or treating wrinkle, or preventing aging.
- the present invention further provides a method for inhibiting collagen degradation of a panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or a Kaempferia pandurata extract comprising the same, thereby particularly preventing or treating wrinkle, or preventing aging.
- the "Kaempferia pandurata extract” disclosed in the present invention refers to an extract obtained from Kaempferia pandurata, also known as Boesenbergia pandurata, comprising the aforesaid panduratin derivative.
- the method for preparing the Kaempferia pandurata extract is not specially limited as long as the panduratin derivative is included in the extract.
- it may be prepared by extracting the whole plant or part (stem, rhizome or leaf) of Kaempferia pandurata (Roxb.) with at least one solvent selected from the group consisting of water, C 1 -C 6 organic solvent and subcritical or supercritical fluid. If necessary, a process of filtration or condensation commonly used in the related art may be further added.
- the C 1 -C 6 organic solvent may be selected from C 1 -C 6 alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane and petroleum ether, but not limited thereto.
- the "supercritical fluid” refers to any substance at a temperature and pressure above its thermodynamic critical point.
- the “subcritical fluid” includes subcritical liquid and gas.
- the subcritical liquid refers to a fluid at temperatures below the supercritical temperature and the saturation temperature.
- the subcritical gas refers to a fluid at temperatures above the saturation temperature and pressures below the supercritical pressure.
- the supercritical fluid and subcritical fluid are used in various fields, including pharmaceutical industry, food industry, cosmetics/perfume industry, chemical industry and energy industry.
- the supercritical fluid and subcritical fluid that may be used in the present invention are not specially limited.
- carbon dioxide nitrogen, nitrous oxide, methane, ethylene, propane, propylene, petroleum ether, ethyl ether, cyclohexane, etc.
- carbon dioxide is preferred because it is easily available, relatively inexpensive, inexplosive, and sufficiently safe for processing.
- Carbon dioxide has a critical temperature of 31.1 °C and a critical pressure of 73.8 atm.
- Kaempferia pandurata was ground, extracted using ethanol, hexane or chloroform solvent, filtered and concentrated to prepare an ethanol, hexane or chloroform extract of Kaempferia pandurata. Further, Kaempferia pandurata was added to a supercritical fluid extractor using carbon dioxide (CO 2 ) as supercritical fluid to prepare a supercritical extract of Kaempferia pandurata (see Example 1).
- CO 2 carbon dioxide
- the “panduratin derivative” refers to a compound selected from the group consisting of the compounds represented by the following Chemical Formulas 1 to 3. Specifically, the compounds represented by Chemical Formulas 1, 2 and 3 are panduratin A, isopanduratin A and 4-hydroxypanduratin A, respectively.
- the panduratin derivative is commercially available or may be prepared according to a known synthesis method. It may be prepared by separating and purifying a Kaempferia pandurata extract or oil obtained by pressing Kaempferia pandurata. For the separation and purification of the panduratin derivative from the Kaempferia pandurata extract, column chromatography or high-performance liquid chromatography (HPLC) using silica gel, activated alumina or various other synthetic resins may be used alone or in combination, although not limited thereto.
- HPLC high-performance liquid chromatography
- dry Kaempferia pandurata was ground and mixed with ethanol. After solvent extraction, the solvent was removed and the resulting extract was concentrated. The concentrated crude extract was mixed with ethyl acetate. After extracting the ethyl acetate soluble component followed by the removal of ethyl acetate, the ethyl acetate soluble component was concentrated and separated depending on polarities. Specifically, at first, development was carried out using a mixture solvent of hexane and ethyl acetate to remove impurities. Then, separation was carried out using a mixture solvent of hexane, chloroform and ethyl acetate. Finally, panduratin A, isopanduratin A or 4-hydroxypanduratin A was obtained (see Fig. 1 and Examples 2 through 4).
- panduratin derivative selected from the group consisting of the compounds represented by Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same has superior anti-aging activity and is excellent in preventing or treating wrinkle.
- panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same has superior cell proliferation activity.
- MTT assay was carried out using fibroblasts
- addition of the panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same induced cell proliferation markedly (see Test Example 1).
- panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same has the activity of inhibiting collagen degradation by suppressing the expression of MMP-1, and promoting collagen synthesis by inducing the synthesis of procollagen.
- the panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same When treated with the panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same, the expression of MMP-1 was suppressed whereas the procollagen synthesis increased (see Test Example 2).
- panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same inhibits collagen degradation and promotes collagen synthesis.
- collagen degradation occurs by the following mechanism.
- extracellular-regulated protein kinase ERK
- Jun-N-terminal kinase JNK
- p38 kinase which belong to mitogen-activated protein kinases (MAPKs)
- MAPKs mitogen-activated protein kinases
- AP-1 activator protein-1
- MMPs matrix metalloproteinase
- c-Jun and c-Fos are known to play a role in the binding of AP-1 with DNA [ Waskiewicz AJ, Cooper JA., Curr. Opin. Cell Biol., 1995; 7: 798 805 ].
- panduratin A When panduratin A was added, the activity of ERK, JNK and p38 kinase, and the binding of AP-1 with DNA were suppressed. Further, the activity of c-Jun and c-Fos was suppressed. As a result, the secretion of MMPs was suppressed. Accordingly, panduratin A was confirmed to have the activity of inhibiting collagen degradation and promoting collagen synthesis (see Test Example 3).
- panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same exhibited a remarkable wrinkle treatment effect (see Test Example 4).
- panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same is excellent in preventing aging, and particularly, excellent in preventing, or treating wrinkle, thereby being used as an effective component of cosmetic, food or pharmaceutical composition.
- Claimed by the present invention are, however, only non-therapeutic methods for improving collagen synthesis and inhibiting collagen degradation and the use of non-therapeutic cosmetic compositions, a food or a nutritional supplement for inhibiting collagen degradation and for promoting collagen synthesis.
- a composition for cosmetics not claimed per se contains the panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same as an effective component, and may be prepared in the form of basic cosmetics (lotions, cream, essence, cleansers such as cleansing foam and cleansing water, pack, body oil), coloring cosmetics (foundation, lip-stick, mascara, make-up base), hair care composition (shampoo, rinse, hair conditioner, hair gel) and soap with dermatologically acceptable excipients.
- basic cosmetics such as cleansing foam and cleansing water, pack, body oil
- coloring cosmetics foundation, lip-stick, mascara, make-up base
- hair care composition shampoo, rinse, hair conditioner, hair gel
- the said excipients may comprise, but not limited thereto, skin softener, skin infiltration enhancer, colorant, odorant, emulsifier, thickener, or solvent.
- a cleanser and soap comprising composition of the present invention, they may be prepared easily by adding the panduratin derivative or the Kaempferia pandurata extract comprising the same to conventional cleanser or soap base.
- a cream In case of manufacturing a cream, it may be prepared by adding the panduratin derivative or the Kaempferia pandurata extract comprising the same to conventional oil-in-water cream base.
- a fragrance In addition, it is possible to add a fragrance, a chelating agent, a pigment, an antioxidant, a preservative, and the like, and to add proteins, minerals or synthetic polymers for improving physical properties.
- the panduratin derivative or the Kaempferia pandurata extract comprising the same of the present invention may be preferably comprised by the form of composition for cosmetics not claimed per se in the range of 0.001-10 wt%, and more preferably 0.01-5 wt%, based on the total weight of a formulation. If the composition is added in an amount of less than 0.001 wt%, it will provide low effect in preventing aging or treating wrinkle, and if it is added in an amount of more than 10 wt%, it will have a difficulty in safety or formulation.
- a composition for food to be used in accordance with the invention may comprise all kinds of forms including functional food, nutritional supplement, health food, and food additives.
- composition for food may be prepared into various kinds of forms by the methods known in the art.
- the panduratin derivative or the Kaempferia pandurata extract comprising the same of the present invention may be prepared into tea, juice, and drink for drinking or may be prepared into granules, capsules, or powder for uptake.
- conventional active ingredient which is well known as having activity in prevention of aging or prevention or treatment of wrinkle may be mixed with the panduratin derivative or the Kaempferia pandurata extract comprising the same of the present invention so as to prepare a composition.
- the panduratin derivative or the Kaempferia pandurata extract comprising the same of the present invention may be added to beverages (including alcoholic beverages), fruits, and their processed foods (e.g.
- panduratin derivative or the Kaempferia pandurata extract comprising the same may be prepared in a form of powder or extract for food additives.
- the panduratin derivative or the Kaempferia pandurata extract comprising the same may be properly comprised by the form of composition for food preferably in the range of 0.01 to 50% based on the total weight of a food. More preferably, a food composition to be used in the invention may be prepared particularly by mixing conventional active ingredient which is well known as having activity in prevention of aging or prevention or treatment of wrinkle with the panduratin derivative or Kaempferia pandurata extract comprising the same of the present invention.
- panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same has superior anti-aging activity and is especially excellent in preventing or treating wrinkle, it can be used for preparing a cosmetic composition, food composition or pharmaceutical composition for anti-aging, preventing or treating wrinkle. Said compositions are not claimed per se.
- the method for preparing the cosmetic composition, food composition or pharmaceutical composition using the panduratin derivative or the Kaempferia pandurata extract is the same as described above. And, the content of the panduratin derivative or the Kaempferia pandurata extract in the compositions is the same as described above.
- the panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same is used in a non-therapeutic cosmetic composition, a food or a nutritional supplement for method for preventing or treating wrinkle, or for preventing aging.
- the panduratin derivative or the Kaempferia pandurata extract may be administered to a subject in need thereof with an effective amount.
- the "subject in need” refers to a mammal, preferably a human, in need of preventing, or treating wrinkle, or preventing aging.
- the "effective amount” refers to an amount which exhibits the effect of preventing or treating wrinkle, and preventing aging by inhibiting collagen degradation and promoting collagen synthesis in the subject.
- the administration method and administration dose for administering with the effective amount are the same as described in detail above.
- the panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same is also used in a non-therapeutic method for promoting collagen synthesis and inhibiting collagen degradation.
- the panduratin derivative selected from the group consisting of the compounds represented by the Chemical Formulas 1 to 3 or the Kaempferia pandurata extract comprising the same induces cell proliferation, inhibits degradation of collagen, and promotes synthesis of collagen; therefore, it shows excellent activity in preventing aging, particularly preventing or treating wrinkle.
- Dry Kaempferia pandurata rhizome was ground using a mixer. 100 g of the ground Kaempferia pandurata sample was added to 1 L of ethanol and extracted at room temperature for 48 hours. The extracted sample was filtered through Whatman No. 2 filter paper. The solvent component was removed from the filtered extract solution by concentrating using a vacuum rotary evaporator. An ethanol extract of Kaempferia pandurata was obtained.
- Dry Kaempferia pandurata rhizome was ground using a mixer. 100 g of the ground Kaempferia pandurata sample was added to 1 L of hexane and extracted at room temperature for 48 hours. The extracted sample was filtered through Whatman No. 2 filter paper. The solvent component was removed from the filtered extract solution by concentrating using a vacuum rotary evaporator. A hexane extract of Kaempferia pandurata was obtained.
- Dry Kaempferia pandurata rhizome was ground using a mixer. 100 g of the ground Kaempferia pandurata sample was added to 1 L of chloroform and extracted at room temperature for 48 hours. The extracted sample was filtered through Whatman No. 2 filter paper. The solvent component was removed from the filtered extract solution by concentrating using a vacuum rotary evaporator. A chloroform extract of Kaempferia pandurata was obtained.
- a supercritical extract was obtained from Kaempferia pandurata rhizome using a supercritical fluid extractor and using carbon dioxide (CO 2 ) as supercritical fluid. After extracting at 50 °C and 200 bar, the solvent component was removed from the extract solution. A supercritical extract was obtained.
- the concentrated ethanol extract of Kaempferia pandurata obtained in Example 1-1 was mixed with ethyl acetate.
- the ethyl acetate soluble component was extracted and ethyl acetate was removed under reduced pressure to concentrate the ethyl acetate soluble component.
- a column in which silica gel was packed with 6 x 15 cm, and using a solvent system consisting of n -hexane, chloroform and ethyl acetate (15 : 5 : 1.5, v/v/v) a total of 6 fractions were concentrated and dried.
- the 3rd fraction (fraction 3) was subjected to thin layer chromatography (TLC, silica gel 60F254, Merck) using a developing solvent consisting of n -hexane, ethyl acetate and methanol (18 : 2 : 1, v/v/v). A total of 3 fractions were concentrated and dried.
- the 2nd fraction (fraction 3-2) was subjected to recycling HPLC (column: W-252, 20.0 mm ID x 500 mm L). A total of 2 fractions were concentrated and dried. Finally, of the 2 fractions, the 2nd fraction (fraction 3-2-2) was concentrated and dried.
- Panduratin A of the following Chemical Formula 1 was isolated as a pure substance having wrinkle treatment activity.
- the concentrated ethanol extract of Kaempferia pandurata obtained in Example 1-1 was mixed with ethyl acetate.
- the ethyl acetate soluble component was extracted and ethyl acetate was removed under reduced pressure to concentrate the ethyl acetate soluble component.
- a column in which silica gel was packed with 6 x 15 cm, and using a solvent system consisting of n -hexane, chloroform and ethyl acetate (15 : 5 : 1.5, v/v/v) a total of 6 fractions were concentrated and dried.
- the 4th fraction was eluted using a reverse phase-18 (Rp-18, LiChropep, 25-40 m) packing material and using a solvent system consisting of methanol and water (9 : 1, v/v). A total of 2 fractions were obtained.
- the 2nd fraction (fraction 4-2) was concentrated, dried and eluted using a solvent system consisting of chloroform and methanol (10 : 0.2, v/v). A total of 2 fractions were concentrated and dried.
- the 2nd fraction (fraction 4-2-2) was eluted using a solvent system consisting of n -hexane and ethyl acetate (10 : 3, v/v). A total of 2 fractions were concentrated and dried.
- the 2nd fraction (fraction 4-2-2-2) was concentrated and dried. Isopanduratin A of the following Chemical Formula 2 was isolated as a pure substance having wrinkle treatment activity.
- the concentrated ethanol extract of Kaempferia pandurata obtained in Example 1-1 was mixed with ethyl acetate.
- the ethyl acetate soluble component was extracted and ethyl acetate was removed under reduced pressure to concentrate the ethyl acetate soluble component.
- a column in which silica gel was packed with 6 x 15 cm, and using a solvent system consisting of n -hexane, chloroform and ethyl acetate (15 : 5 : 1.5, v/v/v) a total of 6 fractions were concentrated and dried.
- the 6th fraction (fraction 6) was eluted using a solvent system consisting of methylene chloride and methanol (19 : 1, v/v). A total of 3 fractions were obtained.
- the 2nd fraction (fraction 6-2) was eluted using a solvent system consisting of chloroform and methanol (20 : 1, v/v). A total of 2 fractions were obtained.
- the 2nd fraction (fraction 6-2-2) was subjected to recycling HPLC (column: W-252, 20.0 mm ID ⁇ 500 mm L). 4-Hydroxypanduratin A of the following Chemical Formula 3 was isolated as a pure substance having wrinkle treatment activity.
- MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction method] was performed on fibroblasts to evaluate cell proliferation of the Kaempferia pandurata ethanol extract prepared in Example 1-1.
- a green tea extract which is known to have skin wrinkle treatment effect, was selected as control substance. The result is given in the following Table 1.
- Table 1 Cell proliferation effect of Kaempferia pandurata extract Proliferation effect (%) Proliferation effect (%) Concentration ( ⁇ g/mL) Kaempferia pandurata extract Green tea extract 0 100 100 0.001 102 101 0.01 103 102 0.1 107 105 1 121 119 10 128 121 50 134 128
- the Kaempferia pandurata extract of the present invention exhibited better cell proliferation effect than the control substance.
- MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction method] was performed on fibroblasts to evaluate cell proliferation of the panduratin derivatives prepared in Examples 2 through 4.
- Epigallocatechin-3-O-gallate (EGCG) which is known to have skin wrinkle treatment effect, was selected as control substance. The result is given in the following Table 2.
- panduratin derivatives of the present invention exhibited better cell proliferation effect than the control substance.
- MMP-1 inhibition activity and procollagen synthesis promotion effect of the Kaempferia pandurata ethanol extract prepared in Example 1 were measured by Western blotting and reverse transcriptase-polymerase chain reaction (RT-PCR). The result is given in Fig. 2 .
- proteins were extracted from cultured fibroblasts and quantitated using a protein assay reagent (Bio-Rad Laboratories Inc., Hercules, CA, USA).
- a protein assay reagent Bio-Rad Laboratories Inc., Hercules, CA, USA.
- the proteins were heated for 3 minutes and, after cooling, transferred to a nitrocellulose membrane (Amersham International, Little Chalfont, England) through electrophoresis in 10% SDS-PAGE.
- the membrane was saturated with 5 % skim milk in TBST (10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% Tween 20).
- TBST 10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% Tween 20
- After blotting for 2 hours using primary antibodies (diluted to 1:1000), followed by washing with TBST, blotting was performed for 2 hours using secondary antibodies (diluted to 1:2000).
- the blotted antibodies were analyzed using an ECL
- RNAs were isolated from fibroblasts using TRIZOL (Invitrogen, USA). The isolated RNAs were quantitated using MMP-1 and procollagen primers and Taq polymerase. Specifically, RT-PCR was carried out using MMP-1 primer for 25 cycles, each cycle consisting of 30 seconds at 94 °C, 1 minute at 50 °C and 1 minute at 72 °C. And RT-PCR was carried out using procollagen primer for 28 cycles, each cycle consisting of 30 seconds at 94 °C, 1 minute at 60 °C and 1 minute at 72 °C. Then, after electrophoresis using 1% agarose gel, expression of mRNA for MMP-1 and procollagen was analyzed through ethidium bromide (EtBr) illumination.
- EtBr ethidium bromide
- Kaempferia pandurata extract can be effectively used for anti-aging or wrinkle treatment because it inhibits the expression of collagenase and promotes procollagen synthesis.
- panduratin derivatives prepared in Examples 2 through 4 were measured by Western blotting and RT-PCR in the same manner as Test Example 2-1. The result is given in Figs. 3-5 .
- panduratin A As seen from Figs. 3-5 , treatment with panduratin A (see Fig. 3 ), isopanduratin A (see Fig. 4 ) or 4-hydroxypanduratin A (see Fig. 5 ) resulted in the decrease of MMP-1 proteins and mRNAs in a concentration-dependent manner, whereas expression of procollagen proteins and mRNAs increased in a concentration-dependent manner. Particularly, they exhibited better activity than the control substance EGCG.
- panduratin derivatives can be effectively used for anti-aging or wrinkle treatment because they inhibit the expression of collagenase and promotes procollagen synthesis.
- Test Example 3 Collagen degradation inhibition mechanism of Kaempferia pandurata extract or panduratin derivatives
- Human skin fibroblasts (CCD-986sk, ATCC, Manassas, VA, USA) were cultured in DMEM (Gibco, Grand Island, NY, USA). The fibroblasts were cultured on a 10 cm Petri dish (SPL, Seoul, Korea) to a concentration of 80% and further cultured for 24 hours in serum-free culture medium. Then, the cells were cultured for 24 hours in serum-free DMEM containing the panduratin A of Example 2. After replacing the culture medium with 5 mL of phosphate-buffered saline (PBS), the cells were exposed to UV (20 mJ/cm 2 ). Cells that were not exposed to UV were used as negative control group, and cells treated with EGCG were used as positive control group.
- PBS phosphate-buffered saline
- the fibroblasts were lysed in RIPA buffer (Sigma-Aldrich Co., St. Louis, MO, USA) and proteins were quantitated using a protein assay reagent (Bio-Rad Laboratories Inc., Hercules, CA, USA). For Western blotting, the proteins were heated for 3 minutes and, after cooling, transferred to a nitrocellulose membrane (Amersham International, Little Chalfont, England) through electrophoresis in 10% SDS-PAGE. The membrane was saturated with 5 % skim milk in TBST (10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% Tween 20).
- ERK, JNK and p38 kinase were activated by phosphorylation when exposed to UV. But, the activation of ERK, JNK and p38 kinase was suppressed in a concentration-dependent manner when panduratin A was added. Considering that the activation of ERK, JNK and p38 kinase by phosphorylation induces the activation of activator protein-1 (AP-1) [ Xu Y, Fisher GJ., J. Dermatol. Sci. Suppl.
- AP-1 activator protein-1
- panduratin A may be effectively used for anti-aging or wrinkle treatment through inhibition of collagen degradation.
- Electrophoretic mobility shift assay was performed to measure the DNA binding activity of AP-1. Specifically, the fibroblasts, which were cultured in Test Example 3-1, to which panduratin A was added and which were exposed to UV, were washed with PBS and collected. After resuspending them in 100 ⁇ L of lysis buffer (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, pH 7.9) for 15 minutes, 30 ⁇ L of 5% NP-40 was added and mixed for 15 seconds.
- lysis buffer (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, pH 7.9
- the cytosol component was removed by centrifuge and nuclear pellets were lysed using extraction buffer (20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, pH 7.9).
- Gel shift assay was carried out using quantitated nuclear proteins according to the manufacturer's instructions (Gel Shift Kit System; Panomics, Fremont, CA, USA). Then, the detected proteins were analyzed with an ECL detection system (Amersham International, Little Chalfont, England) and the detection level was measured using the software RFLPscan version 2.1.
- DNA binding activity of AP-1 was determined through this procedure. The result is given in Fig. 7 .
- panduratin A resulted in inhibited binding of AP-1 to DNA in a concentration-dependent manner. Accordingly, considering that the activation of AP-1 may promote the secretion of MMPs and degradation of collagen, panduratin A may be effectively used for anti-aging or wrinkle treatment through inhibition of collagen degradation.
- panduratin A may inhibit AP-1 activity, as in Test Example 3-2.
- each sample was dissolved in a mixture solvent of ethanol and polyethylene glycol (7:3, v/v) and 50 ⁇ L was applied on the back of the mice every day for 8 weeks.
- 50 ⁇ L of a mixture of ethanol and polyethylene glycol (7:3, v/v) was applied.
- the Kaempferia pandurata ethanol extract-treated group (0.1 % and 0.5 %) and the panduratin A-treated group (1 mM and 5 mM) exhibited remarkably decreased wrinkling as compared to the UV-treated group.
- both the Kaempferia pandurata ethanol extract-treated group and the panduratin A-treated group exhibited significantly decreased Rt, Rm, Rz and Ra values (p ⁇ 0.05).
- the oral administration of the Kaempferia pandurata extract or the panduratin derivative exhibited remarkably decreased wrinkling.
- the oral administration of the Kaempferia pandurata extract or the panduratin derivative provides excellent wrinkle treatment effect.
- Formulation Example 1 Cosmetics (not claimed per se) 1-1 and 1-2. Nourishing lotion (milk lotion)
- Nourishing lotion was prepared according to a method commonly used in the related art using the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1, with the compositions of the following Table 3.
- Table 3 Nourishing lotion (milk lotion) Formulation Example 1-1 (wt%) Formulation Example 1-2 (wt%)
- Softening lotion skin lotion
- Softening lotion was prepared according to a method commonly used in the related art using the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1, with the compositions of the following Table 4.
- Table 4 Softening lotion (skin lotion) Formulation Example 1-3 (wt%) Formulation Example 1-4 (wt%)
- Nourishing cream was prepared according to a method commonly used in the related art using the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1, with the compositions of the following Table 5.
- Table 5 Nourishing cream Formulation Example 1-5 (wt%) Formulation Example 1-6 (wt%)
- Pack was prepared according to a method commonly used in the related art using the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1, with the compositions of the following Table 7.
- Table 7 Pack Formulation Example 1-9 (wt%) Formulation Example 1-10 (wt%)
- Gel was prepared according to a method commonly used in the related art using the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1, with the compositions of the following Table 8.
- Table 8 Gel Formulation Example 1-11 (wt%) Formulation Example 1-12 (wt%)
- Panduratin derivative 0.5 - Kaempferia pandurata extract - 0.5 Ethylenediamine sodium acetate 0.05 0.05 Glycerine 5.0 5.0 5.0 5.0 Carboxyvinyl polymer 0.3 0.3 Ethanol 5.0 5.0 PEG 60 hydrogenated castor oil 0.5 0.5 Triethanolamine 0.3 0.3 Antiseptic, pigment and perfume adequate adequate Purified water to 100 to 100
- 1,000 mg of the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1 may be mixed with 70 ⁇ g of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B 1 , 0.15 mg of vitamin B 2 , 0.5 mg of vitamin B 6 , 0.2 ⁇ g of vitamin B 12 , 10 mg of vitamin C, 10 ⁇ g of biotin, 1.7 mg of nicotinamide, 50 ⁇ g of folic acid, 0.5 mg of calcium pantothenate, 1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of monobasic potassium phosphate, 55 mg of dibasic calcium phosphate, 90 mg of potassium citrate, 100 mg of calcium carbonate and 24.8 mg of magnesium chloride.
- the mixing proportion may be changed differently.
- the mixture may be prepared into granules according to a method commonly used in the related art and may be used for the preparation of a health food composition according to
- 1,000 mg of the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1 may be mixed with 1,000 mg of citric acid, 100 g of oligosaccharide, 2 g of plum extract and 1 g of taurine according to a method commonly used in the related art.
- Purified water may be added to a total volume of 900 mL. After heating at 85 °C for about 1 hour while stirring, the resultant solution may be filtered and collected in a sterilized 2 L container. After sealing and sterilization, it may be kept cold to prepare a health drink composition.
- 0.1 wt% of the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1 may be mixed with 20 wt% of gum base, 76.9 wt% of sugar, 1 wt% of perfume and 2 wt% of water according to a method commonly used in the related art to prepare chewing gum.
- 0.1 wt% of the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1 may be mixed with 60 wt% of sugar, 39.8 wt% of starch syrup and 0.1 wt% of perfume according to a method commonly used in the related art to prepare candy.
- 1 wt% of the panduratin derivative of Examples 2 through 4 or the Kaempferia pandurata extract of Example 1 may be mixed with 25.59 wt% of hard wheat flour, 22.22 wt% of medium wheat flour, 4.80 wt% of refined sugar, 0.73 wt% of table salt, 0.78 wt% of glucose, 11.78 wt% of palm shortening, 1.54 wt% of ammonium, 0.17 wt% of baking soda, 0.16 wt% of sodium bisulfite, 1.45 wt% of rice flour, 0.0001 wt% of vitamin B 1 , 0.0001 wt% of vitamin B 2 , 0.04 wt% of milk flavor, 20.6998 wt% of water, 1.16 wt% of whole milk powder, 0.29 wt% of milk replacer, 0.03 wt% of monobasic calcium phosphate, 0.29 wt% of scattering salt and 7.27 wt% of spray-milk according to a method commonly
- panduratin derivative or the Kaempferia pandurata extract comprising the same induces cell proliferation, inhibits degradation of collagen, and promotes synthesis of collagen, therefore, it shows excellent activity in prevention of aging, particularly preventing or treating wrinkle. While it can be used as an effective ingredient in a cosmetic or food or nutritional supplement, these products are not claimed per se but only non-therapeutic uses of a cosmetic or food or nutritional supplement thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
- Nicht-therapeutische Verwendung einer kosmetischen Zusammensetzung zur Prävention oder Behandlung von Falten, oder zur Prävention der Alterung, wobei die Zusammensetzung die Kollagensynthese fördert, und sie ein Panduratin-Derivat umfasst, ausgewählt aus der Gruppe, bestehend aus den Verbindungen, dargestellt durch die nachfolgenden chemischen Formeln 1 bis 3, oder einem Extrakt aus Kaempferia pandurata, umfassend das Panduratin-Derivat als wirksamen Bestandteil:
- Nicht-therapeutische Verwendung einer kosmetischen Zusammensetzung zur Prävention oder Behandlung von Falten, oder zur Prävention der Alterung, wobei die Zusammensetzung den Kollagenabbau inhibiert, und sie ein Panduratin-Derivat umfasst, ausgewählt aus der Gruppe, bestehend aus den Verbindungen, dargestellt durch die nachfolgenden chemischen Formeln 1 bis 3, oder einem Extrakt aus Kaempferia pandurata, umfassend das Panduratin-Derivat als wirksamen Bestandteil:
- Nicht-therapeutische Verwendung einer kosmetischen Zusammensetzung nach Anspruch 1 oder 2, wobei die Zusammensetzung zur Behandlung von Falten eingesetzt wird, die durch UV-Exposition verursacht werden.
- Nicht-therapeutische Verwendung einer kosmetischen Zusammensetzung nach Anspruch 1 oder 2, wobei der Extrakt aus Kaempferia pandurata mit einem Lösungsmittel extrahiert wird, welches ausgewählt wird aus der Gruppe, bestehend aus Wasser, einem C1-C6 organischen Lösungsmittel und subkritischer oder superkritischer Flüssigkeit.
- Nicht-therapeutische Verwendung einer kosmetischen Zusammensetzung nach Anspruch 4, wobei das C1-C6 organische Lösungsmittel eines ist, welches ausgewählt wird aus der Gruppe, bestehend aus C1-C6 Alkohol, Aceton, Ether, Benzol, Chloroform, Ethylacetat, Methylenchlorid, Hexan, Cyclohexan, und Petrolether.
- Nicht-therapeutisches Verfahren zur Förderung der Kollagensynthese unter Verwendung eines Panduratin-Derivats, ausgewählt aus der Gruppe, bestehend aus den Verbindungen, dargestellt durch die nachfolgenden chemischen Formeln 1-3 oder einem Extrakt aus Kaempferia pandurata, umfassend das Panduratin-Derivat als eine wirksame Verbindung:
- Nicht-therapeutisches Verfahren zur Inhibierung des Kollagenabbaus unter Verwendung eines Panduratin-Derivats, ausgewählt aus der Gruppe, bestehend aus den Verbindungen, dargestellt durch die nachfolgenden chemischen Formeln 1-3 oder einem Extrakt aus Kaempferia pandurata, umfassend das Panduratin-Derivat als eine wirksame Verbindung:
- Nicht-therapeutisches Verfahren nach Anspruch 6 oder 7, wobei der Extrakt aus Kaempferia pandurata mit einem Lösungsmittel extrahiert wird, welches ausgewählt wird aus der Gruppe, bestehend aus Wasser, einem C1-C6 organischen Lösungsmittel und subkritischer oder superkritischer Flüssigkeit.
- Nicht-therapeutisches Verfahren nach Anspruch 8, wobei das C1-C6 organische Lösungsmittel eines ist, welches ausgewählt wird aus der Gruppe, bestehend aus C1-C6 Alkohol, Aceton, Ether, Benzol, Chloroform, Ethylacetat, Methylenchlorid, Hexan, Cyclohexan, und Petrolether.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20070104788 | 2007-10-17 | ||
PCT/KR2008/006137 WO2009051434A1 (en) | 2007-10-17 | 2008-10-17 | Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2200574A1 EP2200574A1 (de) | 2010-06-30 |
EP2200574A4 EP2200574A4 (de) | 2015-11-18 |
EP2200574B1 true EP2200574B1 (de) | 2019-06-26 |
Family
ID=40567579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08840361.3A Active EP2200574B1 (de) | 2007-10-17 | 2008-10-17 | Neue verwendung von panduratin-derivaten oder kaempferia pandurata-extrakt damit |
Country Status (6)
Country | Link |
---|---|
US (2) | US20120065272A1 (de) |
EP (1) | EP2200574B1 (de) |
JP (2) | JP2011500669A (de) |
KR (1) | KR101088069B1 (de) |
CN (1) | CN101827576B (de) |
WO (1) | WO2009051434A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI123498B (fi) * | 2008-07-01 | 2013-05-31 | Upm Kymmene Oyj | Menetelmä oksapuu-uutteen fraktioimiseksi ja neste-nesteuuton käyttö oksapuu-uutteen puhdistamiseksi |
KR101640735B1 (ko) * | 2010-03-09 | 2016-07-29 | 주식회사 엘지생활건강 | 주름 개선용 조성물 |
KR101698201B1 (ko) * | 2010-05-20 | 2017-01-19 | (주)뉴트리 | 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물을 포함하는 근육 증가 촉진, 항-피로 및 운동수행능력 향상용 조성물 |
KR101434653B1 (ko) * | 2011-01-21 | 2014-08-26 | 연세대학교 산학협력단 | 플라본계 화합물의 신규한 용도 |
KR101319522B1 (ko) * | 2011-11-08 | 2013-10-21 | 롯데제과주식회사 | 충치 및 치주염에 유효한 구강위생 조성물 |
KR102050351B1 (ko) | 2018-05-17 | 2019-12-02 | 이호규 | 핑거루트 추출물의 독성 제거방법 및 이 방법에 의하여 독성이 제거된 핑거루트 추출물을 함유하는 피부 항상성 무독성 화장료 조성물 |
KR102288066B1 (ko) | 2019-08-19 | 2021-08-11 | 이호규 | 천연식물 화장품소재 핑거루트의 추출방법 및 그 추출물을 함유하는 피부탄력 화장료 조성물 및 그 제조방법 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61291515A (ja) * | 1985-06-19 | 1986-12-22 | Shiseido Co Ltd | 化粧料 |
JPH08157346A (ja) * | 1994-12-07 | 1996-06-18 | Shiseido Co Ltd | 紫外線吸収性皮膚化粧料 |
JPH0930948A (ja) * | 1995-07-21 | 1997-02-04 | Shiseido Co Ltd | 美白用皮膚外用剤 |
JPH0930945A (ja) | 1995-07-21 | 1997-02-04 | Shiseido Co Ltd | 皮膚外用剤 |
JP2000316526A (ja) | 1999-04-30 | 2000-11-21 | Bio Pure Co Ltd | 薬草を含んでなる食品組成物 |
JP2001261545A (ja) | 2000-03-21 | 2001-09-26 | Shiseido Co Ltd | 肌荒れ防止用皮膚外用剤 |
CA2414406A1 (en) * | 2000-06-26 | 2002-01-03 | The Regents Of The University Of Michigan | Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
AU2001286578A1 (en) | 2000-08-24 | 2002-03-04 | Tim Ioannides | Topical antioxidant having vitamin c and method of combination with topical agent by user |
JP4866501B2 (ja) * | 2000-10-13 | 2012-02-01 | 日本メナード化粧品株式会社 | 皮膚外用剤 |
JP2003128515A (ja) * | 2001-10-17 | 2003-05-08 | Toshikatsu Imamura | 化粧料 |
KR100492034B1 (ko) | 2002-01-09 | 2005-05-31 | 황재관 | 판두라틴 유도체를 함유하는 충치 및 치주염 예방과치료용 항균제 및 구강 조성물 |
JP3827581B2 (ja) * | 2002-01-31 | 2006-09-27 | 丸善製薬株式会社 | 皮膚化粧料及び美容用飲食品 |
WO2004058213A1 (en) * | 2002-12-27 | 2004-07-15 | Hankook Pharm. Co., Inc. | Extract of cercis chinensis having anti-oxidant activity and anti-aging activity, and cosmetical composition containing the extract for anti-oxidation, skin-aging protection and wrinkle improvement |
KR20060041161A (ko) * | 2003-04-10 | 2006-05-11 | 라이트 바이오사이언스, 엘엘씨 | 세포 증식 및 유전자 발현의 조절을 위한 광조절 방법 및광조절 장치 |
KR20040108081A (ko) | 2003-06-16 | 2004-12-23 | 부산대학교 산학협력단 | 단삼유래 천연물 디메틸리소스퍼메이트를 유효성분으로하는 항산화제 및 항노화제 |
JP4739202B2 (ja) * | 2003-07-31 | 2011-08-03 | ジェントルウェイブス エルエルシー | 熱傷、創傷、および関連皮膚疾患の光力学治療のためのシステムおよび方法 |
JP4224387B2 (ja) * | 2003-12-04 | 2009-02-12 | 日本メナード化粧品株式会社 | 皮膚外用剤 |
JP2005281174A (ja) * | 2004-03-29 | 2005-10-13 | Sanei Seiyaku Kk | 活性酸素消去剤 |
JP2006008531A (ja) * | 2004-06-22 | 2006-01-12 | Nagase & Co Ltd | 抗酸化酵素産生促進剤及びその製造方法。 |
US7348034B2 (en) * | 2005-03-07 | 2008-03-25 | Access Business Group International Llc | Plant based formulations for improving skin moisture, texture, and appearance |
JP2007186431A (ja) | 2006-01-11 | 2007-07-26 | Pharmish Inc | 抗酸化組成物及び脳神経細胞保護用医薬組成物、抗酸化剤及び脳神経細胞保護剤、並びにそれらの使用方法 |
WO2008023966A1 (en) * | 2006-08-25 | 2008-02-28 | Industry-Academic Cooperation Foundation, Yonsei University | Novel use of panduratin a or derivatives thereof |
JP2009051790A (ja) * | 2007-08-29 | 2009-03-12 | Maruzen Pharmaceut Co Ltd | 抗酸化剤、抗老化剤、抗炎症剤、育毛剤、抗肥満剤、及び美白剤、並びに化粧料及び美容用飲食品 |
-
2008
- 2008-10-17 US US12/738,591 patent/US20120065272A1/en not_active Abandoned
- 2008-10-17 KR KR1020080102060A patent/KR101088069B1/ko active IP Right Grant
- 2008-10-17 CN CN2008801121985A patent/CN101827576B/zh active Active
- 2008-10-17 EP EP08840361.3A patent/EP2200574B1/de active Active
- 2008-10-17 JP JP2010529872A patent/JP2011500669A/ja active Pending
- 2008-10-17 WO PCT/KR2008/006137 patent/WO2009051434A1/en active Application Filing
-
2014
- 2014-03-13 JP JP2014049951A patent/JP5931944B2/ja active Active
-
2015
- 2015-12-17 US US14/972,520 patent/US20160271028A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
US20160271028A1 (en) | 2016-09-22 |
KR20090039649A (ko) | 2009-04-22 |
CN101827576B (zh) | 2013-05-01 |
CN101827576A (zh) | 2010-09-08 |
WO2009051434A1 (en) | 2009-04-23 |
JP2014111660A (ja) | 2014-06-19 |
EP2200574A4 (de) | 2015-11-18 |
KR101088069B1 (ko) | 2011-11-29 |
EP2200574A1 (de) | 2010-06-30 |
US20120065272A1 (en) | 2012-03-15 |
JP2011500669A (ja) | 2011-01-06 |
JP5931944B2 (ja) | 2016-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2200576B1 (de) | Neue verwendung von aus muskatextrakt oder muskatarillusextrakt isolierten lignanverbindungen | |
US20160271028A1 (en) | Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same | |
EP2170255B1 (de) | Verwendung einer lignan-verbindung zur behandlung von falten | |
KR101599763B1 (ko) | 여드름 개선용 조성물 | |
KR101758144B1 (ko) | 이고들빼기 추출물을 포함하는 항노화 조성물 | |
KR102283527B1 (ko) | 곡류 발효 추출물을 유효성분으로 함유하는 화장료 조성물 | |
JP6173362B2 (ja) | 皮膚バリア機能改善剤、細胞間接着構造の形成促進剤、タイトジャンクション形成促進剤、TRPV4活性化剤、細胞内Ca濃度上昇亢進剤及び皮脂産生促進剤 | |
KR101914441B1 (ko) | 퓨코스테롤을 유효성분으로 포함하는 피부 보습용 화장료 조성물 | |
KR101904501B1 (ko) | 퓨코스테롤을 유효성분으로 포함하는 피부주름 개선 또는 피부탄력 증진용 화장료 조성물 | |
KR20180090123A (ko) | 리퀴댐버릭 락톤을 포함하는 화장료 조성물 | |
WO2008156330A1 (en) | Use of xanthorrhizol for anti-wrinkle treatment | |
JP2011032177A (ja) | Kit切断抑制剤 | |
KR20070121193A (ko) | 청주 순미주 농축물 및 청주박 추출물 중 어느 하나 이상을함유하는 피부 보호 또는 염증 완화용 조성물 | |
KR101526435B1 (ko) | 머루근 추출물을 포함하는 미백용 조성물 | |
KR102326086B1 (ko) | 닥나무 복합 추출물을 유효성분으로 포함하는 피부 미백, 주름개선, 보습, 및 피부장벽 강화용 조성물 | |
KR102557210B1 (ko) | 데쿠시놀을 유효성분으로 포함하는 항당화용 조성물 | |
KR20140057040A (ko) | 피페린계 화합물을 유효성분으로 포함하는 피부노화 개선용 조성물 | |
KR102526200B1 (ko) | 데쿠시놀을 유효성분으로 포함하는 피부 보습 및 미백용 조성물 | |
KR102401490B1 (ko) | 당귀 추출물을 유효성분으로 함유하는 피부미백 개선 및 자외선 차단용 화장료 조성물 | |
KR102194314B1 (ko) | 락토바실러스 람노서스 균주를 접종하여 발효시킨 녹차 발효 추출물을 포함하는 항산화용 또는 피부 마이크로바이옴 균형 유지용 화장료 조성물 | |
KR102014960B1 (ko) | 콩뿌리 추출물을 함유하는 항산화용 조성물 | |
KR102134968B1 (ko) | 우절 추출물 및 미숙사과 추출물을 포함하는 피부 미백용 화장료 조성물 | |
KR102700608B1 (ko) | 레마피크로사이드를 포함하는 화장료 조성물 | |
JP6291466B2 (ja) | 皮膚バリア機能改善剤、細胞間接着構造の形成促進剤、タイトジャンクション形成促進剤、TRPV4活性化剤、細胞内Ca濃度上昇亢進剤及び皮脂産生促進剤 | |
AU2020260940A2 (en) | Composition comprising Actinidia polygama extract for alleviating skin damage or moisturizing skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100416 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20151019 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 8/35 20060101AFI20151013BHEP Ipc: A61K 8/97 20060101ALI20151013BHEP Ipc: A61Q 19/08 20060101ALI20151013BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170314 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180928 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CHOI, EUN JUNG Inventor name: WHANG, JAE-KWAN Inventor name: HAN, YOUNG SUN Inventor name: KWON, YI YOUNG Inventor name: OH, HYUN IN Inventor name: SHIM, JAE-SEOK Inventor name: GWON, SONG HUI Inventor name: KIM, DO UN |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20190306 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SHIM, JAE-SEOK Inventor name: GWON, SONG HUI Inventor name: HWANG, JAE-KWAN Inventor name: HAN, YOUNG SUN Inventor name: KWON, YI YOUNG Inventor name: CHOI, EUN JUNG Inventor name: OH, HYUN IN Inventor name: KIM, DO UN |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1147472 Country of ref document: AT Kind code of ref document: T Effective date: 20190715 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008060530 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190926 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190927 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190926 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1147472 Country of ref document: AT Kind code of ref document: T Effective date: 20190626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191028 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191026 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008060530 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191017 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191031 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191031 |
|
26N | No opposition filed |
Effective date: 20200603 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20191031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191017 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20081017 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230824 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230821 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230822 Year of fee payment: 16 |